Epigenetic Modifications in the Pathogenesis of Systemic Sclerosis

References

• Orvain C, Assassi S, Avouac J, et al. Systemic sclerosis pathogenesis: contribution of recent advances in genetics. Curr Opin Rheumatol. 2020;32(6):505–514. doi:10.1097/BOR.0000000000000735
   PubMed Web of Science ®Google Scholar
• Ferri C, Arcangeletti M-C, Caselli E, et al. Insights into the knowledge of complex diseases: environmental infectious/toxic agents as potential etiopathogenetic factors of systemic sclerosis. J Autoimmun. 2021;124:102727. doi:10.1016/j.jaut.2021.102727
   PubMed Web of Science ®Google Scholar
• Hughes M, Pauling JD, Armstrong-James L, et al. Gender-related differences in systemic sclerosis. Autoimmun Rev. 2020;19(4):102494. doi:10.1016/j.autrev.2020.102494
   PubMed Web of Science ®Google Scholar
• Zuber JP, Spertini F. Immunological basis of systemic sclerosis. Rheumatology (Oxford). 2006;45 Suppl 3:iii23–25. doi:10.1093/rheumatology/kel285
   PubMed Web of Science ®Google Scholar
• Pattanaik D, Brown M, Postlethwaite BC, et al. Pathogenesis of systemic sclerosis. Front Immunol. 2015;6:272. doi:10.3389/fimmu.2015.00272
   PubMed Web of Science ®Google Scholar
• van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–1755. doi:10.1136/annrheumdis-2013-204424
   PubMed Web of Science ®Google Scholar
• Arnett FC, Cho M, Chatterjee S, et al. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum. 2001;44(6):1359–1362. doi:10.1002/1529-0131(200106)44:6<1359::AID-ART228>3.0.CO;2-S
   PubMed Web of Science ®Google Scholar
• Barnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol. 2012;24(2):165–170. doi:10.1097/BOR.0b013e32834ff2e8
   PubMed Web of Science ®Google Scholar
• Feghali-Bostwick C, Medsger TJ, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum. 2003;48(7):1956–1963. doi:10.1002/art.11173
   PubMed Web of Science ®Google Scholar
• Luo Y, Wang Y, Shu Y, et al. Epigenetic mechanisms: an emerging role in pathogenesis and its therapeutic potential in systemic sclerosis. Int J Biochem Cell Biol. 2015;67:92–100. doi:10.1016/j.biocel.2015.05.023
   PubMed Web of Science ®Google Scholar
• Wu H, Chen Y, Zhu H, et al. The pathogenic role of dysregulated epigenetic modifications in autoimmune diseases. Front Immunol. 2019;10:2305. doi:10.3389/fimmu.2019.02305
   PubMed Web of Science ®Google Scholar
• Schubeler D. Function and information content of DNA methylation. Nature. 2015;517(7534):321–326. doi:10.1038/nature14192
   PubMed Web of Science ®Google Scholar
• Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell. 2007;128(4):669–681. doi:10.1016/j.cell.2007.01.033
   PubMed Web of Science ®Google Scholar
• Jurkowska RZ, Jeltsch A. Mechanisms and biological roles of DNA methyltransferases and DNA methylation: from past achievements to future challenges. Adv Exp Med Biol. 2016;945:1–17.
   PubMed Web of Science ®Google Scholar
• Rothbart SB, Strahl BD. Interpreting the language of histone and DNA modifications. Biochim Biophys Acta. 2014;1839(8):627–643. doi:10.1016/j.bbagrm.2014.03.001
   PubMed Web of Science ®Google Scholar
• Kouzarides T. Chromatin modifications and their function. Cell. 2007;128(4):693–705. doi:10.1016/j.cell.2007.02.005
   PubMed Web of Science ®Google Scholar
• Wapenaar H, Dekker FJ. Histone acetyltransferases: challenges in targeting bi-substrate enzymes. Clin Epigenetics. 2016;8:59. doi:10.1186/s13148-016-0225-2
   PubMed Web of Science ®Google Scholar
• Song Y, Wu F, Wu J. Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives. J Hematol Oncol. 2016;9(1):49. doi:10.1186/s13045-016-0279-9
   PubMed Web of Science ®Google Scholar
• Zhao C-N, Mao Y-M, Liu L-N, et al. Emerging role of lncRNAs in systemic lupus erythematosus. Biomed Pharmacother. 2018;106:584–592. doi:10.1016/j.biopha.2018.06.175
   PubMed Web of Science ®Google Scholar
• Winter J, Jung S, Keller S, et al. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009;11(3):228–234. doi:10.1038/ncb0309-228
   PubMed Web of Science ®Google Scholar
• Zhang T, Hu J, Wang X, et al. MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-kappaB-TNFalpha pathway. J Hepatol. 2019;70(1):87–96. doi:10.1016/j.jhep.2018.08.026
   PubMed Web of Science ®Google Scholar
• Robinson EK, Covarrubias S, Carpenter S. The how and why of lncRNA function: an innate immune perspective. Biochim Biophys Acta Gene Regul Mech. 2020;1863(4):194419. doi:10.1016/j.bbagrm.2019.194419
   PubMed Web of Science ®Google Scholar
• Zhao M, Zhou Y, Zhu B, et al. IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus. Ann Rheum Dis. 2016;75(11):1998–2006. doi:10.1136/annrheumdis-2015-208410
   PubMed Web of Science ®Google Scholar
• Christmann RB, Hayes E, Pendergrass S, et al. Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Rheum. 2011;63(6):1718–1728. doi:10.1002/art.30318
   PubMed Web of Science ®Google Scholar
• Bos CL, van Baarsen LGM, Timmer TCG, et al. Molecular subtypes of systemic sclerosis in association with anti-centromere antibodies and digital ulcers. Genes Immun. 2009;10(3):210–218. doi:10.1038/gene.2008.98
   PubMed Web of Science ®Google Scholar
• Tan FK, Zhou X, Mayes MD, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford). 2006;45(6):694–702. doi:10.1093/rheumatology/kei244
   PubMed Web of Science ®Google Scholar
• Ramos PS, Zimmerman KD, Haddad S, et al. Integrative analysis of DNA methylation in discordant twins unveils distinct architectures of systemic sclerosis subsets. Clin Epigenetics. 2019;11(1):58. doi:10.1186/s13148-019-0652-y
   PubMed Web of Science ®Google Scholar
• Chen S, Pu W, Guo S, et al. Genome-wide DNA methylation profiles reveal common epigenetic patterns of interferon-related genes in multiple autoimmune diseases. Front Genet. 2019;10:223. doi:10.3389/fgene.2019.00223
   PubMed Web of Science ®Google Scholar
• Chen K, Liu J, Cao X. Regulation of type I interferon signaling in immunity and inflammation: a comprehensive review. J Autoimmun. 2017;83:1–11. doi:10.1016/j.jaut.2017.03.008
   PubMed Web of Science ®Google Scholar
• Bujor AM, El Adili F, Parvez A, et al. Fli1 downregulation in scleroderma myeloid cells has profibrotic and proinflammatory effects. Front Immunol. 2020;11:800. doi:10.3389/fimmu.2020.00800
   PubMed Web of Science ®Google Scholar
• Kim D, Peck A, Santer D, et al. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum. 2008;58(7):2163–2173. doi:10.1002/art.23486
   PubMed Web of Science ®Google Scholar
• Assassi S, Mayes MD, Arnett FC, et al. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum. 2010;62(2):589–598. doi:10.1002/art.27224
   PubMed Web of Science ®Google Scholar
• Wang YY, Wang Q, Sun XH, et al. DNA hypermethylation of the forkhead box protein 3 (FOXP3) promoter in CD4+ T cells of patients with systemic sclerosis. Br J Dermatol. 2014;171(1):39–47. doi:10.1111/bjd.12913
   PubMed Web of Science ®Google Scholar
• Matatiele P, Tikly M, Tarr G, et al. DNA methylation similarities in genes of black South Africans with systemic lupus erythematosus and systemic sclerosis. J Biomed Sci. 2015;22(1):34. doi:10.1186/s12929-015-0142-2
   PubMed Web of Science ®Google Scholar
• Lian X, Xiao R, Hu X, et al. DNA demethylation of CD40l in CD4+ T cells from women with systemic sclerosis: a possible explanation for female susceptibility. Arthritis Rheum. 2012;64(7):2338–2345. doi:10.1002/art.34376
   PubMed Web of Science ®Google Scholar
• Zhu H, Zhu C, Mi W, et al. Integration of genome-wide DNA methylation and transcription uncovered aberrant methylation-regulated genes and pathways in the peripheral blood mononuclear cells of systemic sclerosis. Int J Rheumatol. 2018;2018:7342472. doi:10.1155/2018/7342472
   PubMed Web of Science ®Google Scholar
• Altorok N, Tsou P-S, Coit P, et al. Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies. Ann Rheum Dis. 2015;74(8):1612–1620. doi:10.1136/annrheumdis-2014-205303
   PubMed Web of Science ®Google Scholar
• Hattori M, Yokoyama Y, Hattori T, et al. Global DNA hypomethylation and hypoxia-induced expression of the ten eleven translocation (TET) family, TET1, in scleroderma fibroblasts. Exp Dermatol. 2015;24(11):841–846. doi:10.1111/exd.12767
   PubMed Web of Science ®Google Scholar
• Zhang Y, Pötter S, Chen C-W, et al. Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis. Ann Rheum Dis. 2018;77(5):744–751. doi:10.1136/annrheumdis-2017-212265
   PubMed Web of Science ®Google Scholar
• Baker FD, da Silveira W, Hazard ES, et al. Differential DNA methylation landscape in skin fibroblasts from African Americans with systemic sclerosis. Genes (Basel). 2021;12(2):129.
   PubMed Web of Science ®Google Scholar
• Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum. 2006;54(7):2271–2279. doi:10.1002/art.21948
   PubMed Web of Science ®Google Scholar
• Noda S, Asano Y, Nishimura S, et al. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. Nat Commun. 2014;5(1):5797. doi:10.1038/ncomms6797
   PubMed Web of Science ®Google Scholar
• Henderson J, Brown M, Horsburgh S, et al. Methyl cap binding protein 2: a key epigenetic protein in systemic sclerosis. Rheumatology (Oxford). 2019;58(3):527–535. doi:10.1093/rheumatology/key327
   PubMed Web of Science ®Google Scholar
• He Y, Tsou P-S, Khanna D, et al. Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts. Ann Rheum Dis. 2018;77(8):1208–1218. doi:10.1136/annrheumdis-2018-213022
   PubMed Web of Science ®Google Scholar
• Marden G, Wan Q, Wilks J, et al. The role of the oncostatin M/OSM receptor beta axis in activating dermal microvascular endothelial cells in systemic sclerosis. Arthritis Res Ther. 2020;22(1):179. doi:10.1186/s13075-020-02266-0
   PubMed Web of Science ®Google Scholar
• Takagi K, Kawamoto M, Higuchi T, et al. Single nucleotide polymorphisms of the HIF1A gene are associated with susceptibility to pulmonary arterial hypertension in systemic sclerosis and contribute to SSc-PAH disease severity. Int J Rheum Dis. 2020;23(5):674–680. doi:10.1111/1756-185X.13822
   PubMed Web of Science ®Google Scholar
• Nakamura K, Taniguchi T, Hirabayashi M, et al. Altered properties of endothelial cells and mesenchymal stem cells underlying the development of scleroderma-like vasculopathy in KLF5 +/−;Fli-1 +/− Mice. Arthritis Rheumatol. 2020;72(12):2136–2146. doi:10.1002/art.41423
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhu H, Layritz F, et al. Recombinant adenosine deaminase ameliorates inflammation, vascular disease, and fibrosis in preclinical models of systemic sclerosis. Arthritis Rheumatol. 2020;72(8):1385–1395. doi:10.1002/art.41259
   PubMed Web of Science ®Google Scholar
• Wang Y, Kahaleh B. Epigenetic repression of bone morphogenetic protein receptor II expression in scleroderma. J Cell Mol Med. 2013;17(10):1291–1299. doi:10.1111/jcmm.12105
   PubMed Web of Science ®Google Scholar
• Fish JE, Marsden PA. Endothelial nitric oxide synthase: insight into cell-specific gene regulation in the vascular endothelium. Cell Mol Life Sci. 2006;63(2):144–162. doi:10.1007/s00018-005-5421-8
   PubMed Web of Science ®Google Scholar
• Ramahi A, Altorok N, Kahaleh B. Epigenetics and systemic sclerosis: an answer to disease onset and evolution? Eur J Rheumatol. 2020;7(Suppl 3):S147–S156. doi:10.5152/eurjrheum.2020.19112
   PubMed Web of Science ®Google Scholar
• Zhu HL, Du Q, Chen WL, et al. [Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms]. Beijing Da Xue Xue Bao Yi Xue Ban. 2019;51(4):716–722. Chinese. doi:10.19723/j.issn.1671-167X.2019.04.021
   PubMedGoogle Scholar
• Wang Y, Yang Y, Luo Y, et al. Aberrant histone modification in peripheral blood B cells from patients with systemic sclerosis. Clin Immunol. 2013;149(1):46–54. doi:10.1016/j.clim.2013.06.006
   PubMed Web of Science ®Google Scholar
• Ciechomska M, O’Reilly S, Przyborski S, et al. Histone demethylation and toll-like receptor 8-Dependent cross-talk in monocytes promotes transdifferentiation of fibroblasts in systemic sclerosis Via Fra-2. Arthritis Rheumatol. 2016;68(6):1493–1504. doi:10.1002/art.39602
   PubMed Web of Science ®Google Scholar
• van der Kroef M, Castellucci M, Mokry M, et al. Histone modifications underlie monocyte dysregulation in patients with systemic sclerosis, underlining the treatment potential of epigenetic targeting. Ann Rheum Dis. 2019;78(4):529–538. doi:10.1136/annrheumdis-2018-214295
   PubMed Web of Science ®Google Scholar
• Tsou PS, Varga J, O’Reilly S. Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential. Nat Rev Rheumatol. 2021;17(10):596–607. doi:10.1038/s41584-021-00683-2
   PubMed Web of Science ®Google Scholar
• Kramer M, Dees C, Huang J, et al. Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Ann Rheum Dis. 2013;72(4):614–620. doi:10.1136/annrheumdis-2012-201615
   PubMed Web of Science ®Google Scholar
• Tsou PS, Campbell P, Amin MA, et al. Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma. Proc Natl Acad Sci U S A. 2019;116(9):3695–3702. doi:10.1073/pnas.1813006116
   PubMed Web of Science ®Google Scholar
• Wasson CW, Abignano G, Hermes H, et al. Long non-coding RNA HOTAIR drives EZH2-dependent myofibroblast activation in systemic sclerosis through miRNA 34a-dependent activation of NOTCH. Ann Rheum Dis. 2020;79(4):507–517. doi:10.1136/annrheumdis-2019-216542
   PubMed Web of Science ®Google Scholar
• Tsou P-S, Wren JD, Amin MA, et al. Histone deacetylase 5 is overexpressed in scleroderma endothelial cells and impairs angiogenesis via repression of proangiogenic factors. Arthritis Rheumatol. 2016;68(12):2975–2985. doi:10.1002/art.39828
   PubMed Web of Science ®Google Scholar
• Huber LC, Distler JHW, Moritz F, et al. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum. 2007;56(8):2755–2764. doi:10.1002/art.22759
   PubMed Web of Science ®Google Scholar
• Maleszewska M, Vanchin B, Harmsen MC, et al. The decrease in histone methyltransferase EZH2 in response to fluid shear stress alters endothelial gene expression and promotes quiescence. Angiogenesis. 2016;19(1):9–24. doi:10.1007/s10456-015-9485-2
   PubMed Web of Science ®Google Scholar
• Chouri E, Servaas NH, Bekker CPJ, et al. Serum microRNA screening and functional studies reveal miR-483-5p as a potential driver of fibrosis in systemic sclerosis. J Autoimmun. 2018;89:162–170. doi:10.1016/j.jaut.2017.12.015
   PubMed Web of Science ®Google Scholar
• Koba S, Jinnin M, Inoue K, et al. Expression analysis of multiple microRNAs in each patient with scleroderma. Exp Dermatol. 2013;22(7):489–491. doi:10.1111/exd.12173
   PubMed Web of Science ®Google Scholar
• Ciechomska M, Zarecki P, Merdas M, et al. The role of microRNA-5196 in the pathogenesis of systemic sclerosis. Eur J Clin Invest. 2017;47(8):555–564. doi:10.1111/eci.12776
   PubMed Web of Science ®Google Scholar
• Rossato M, Affandi AJ, Thordardottir S, et al. Association of MicroRNA-618 expression with altered frequency and activation of plasmacytoid dendritic cells in patients with systemic sclerosis. Arthritis Rheumatol. 2017;69(9):1891–1902. doi:10.1002/art.40163
   PubMed Web of Science ®Google Scholar
• Christmann RB, Wooten A, Sampaio-Barros P, et al. miR-155 in the progression of lung fibrosis in systemic sclerosis. Arthritis Res Ther. 2016;18(1):155. doi:10.1186/s13075-016-1054-6
   PubMed Web of Science ®Google Scholar
• Jiang Z, Tao J-H, Zuo T, et al. The correlation between miR-200c and the severity of interstitial lung disease associated with different connective tissue diseases. Scand J Rheumatol. 2017;46(2):122–129. doi:10.3109/03009742.2016.1167950
   PubMed Web of Science ®Google Scholar
• Wuttge DM, Carlsen AL, Teku G, et al. Specific autoantibody profiles and disease subgroups correlate with circulating micro-RNA in systemic sclerosis. Rheumatology (Oxford). 2015;54(11):2100–2107. doi:10.1093/rheumatology/kev234
   PubMed Web of Science ®Google Scholar
• Liakouli V, Cipriani P, Di Benedetto P, et al. Epidermal growth factor like-domain 7 and miR-126 are abnormally expressed in diffuse systemic sclerosis fibroblasts. Sci Rep. 2019;9(1):4589. doi:10.1038/s41598-019-39485-8
   PubMed Web of Science ®Google Scholar
• Stypinska B, Wajda A, Walczuk E, et al. The serum cell-free microRNA expression profile in MCTD, SLE, SSc, and RA patients. J Clin Med. 2020;9(1):161. doi:10.3390/jcm9010161
   PubMed Web of Science ®Google Scholar
• Jafarinejad-Farsangi S, Gharibdoost F, Farazmand A, et al. MicroRNA-21 and microRNA-29a modulate the expression of collagen in dermal fibroblasts of patients with systemic sclerosis. Autoimmunity. 2019;52(3):108–116. doi:10.1080/08916934.2019.1621856
   PubMed Web of Science ®Google Scholar
• Zhu H, Luo H, Li Y, et al. MicroRNA-21 in scleroderma fibrosis and its function in TGF-beta-regulated fibrosis-related genes expression. J Clin Immunol. 2013;33(6):1100–1109. doi:10.1007/s10875-013-9896-z
   PubMed Web of Science ®Google Scholar
• O’Reilly S. miRNA-29a in systemic sclerosis: a valid target. Autoimmunity. 2015;48(8):511–512. doi:10.3109/08916934.2015.1077232
   PubMed Web of Science ®Google Scholar
• Maurer B, Stanczyk J, Jüngel A, et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 2010;62(6):1733–1743. doi:10.1002/art.27443
   PubMed Web of Science ®Google Scholar
• Jafarinejad-Farsangi S, Farazmand A, Mahmoudi M, et al. MicroRNA-29a induces apoptosis via increasing the Bax: bcl-2 ratio in dermal fibroblasts of patients with systemic sclerosis. Autoimmunity. 2015;48(6):369–378. doi:10.3109/08916934.2015.1030616
   PubMed Web of Science ®Google Scholar
• Jafarinejad-Farsangi S, Farazmand A, Gharibdoost F, et al. Inhibition of MicroRNA-21 induces apoptosis in dermal fibroblasts of patients with systemic sclerosis. Int J Dermatol. 2016;55(11):1259–1267. doi:10.1111/ijd.13308
   PubMed Web of Science ®Google Scholar
• Mullenbrock S, Liu F, Szak S, et al. Systems analysis of transcriptomic and proteomic profiles identifies novel regulation of fibrotic programs by miRNAs in pulmonary fibrosis fibroblasts. Genes (Basel). 2018;9(12):588. doi:10.3390/genes9120588
   PubMed Web of Science ®Google Scholar
• Henderson J, Distler J, O’Reilly S. The role of epigenetic modifications in systemic sclerosis: a druggable target. Trends Mol Med. 2019;25(5):395–411. doi:10.1016/j.molmed.2019.02.001
   PubMed Web of Science ®Google Scholar
• Long H, Wang X, Chen Y, et al. Dysregulation of microRNAs in autoimmune diseases: pathogenesis, biomarkers and potential therapeutic targets. Cancer Lett. 2018;428:90–103. doi:10.1016/j.canlet.2018.04.016
   PubMed Web of Science ®Google Scholar
• Wermuth PJ, Piera-Velazquez S, Rosenbloom J, et al. Existing and novel biomarkers for precision medicine in systemic sclerosis. Nat Rev Rheumatol. 2018;14(7):421–432. doi:10.1038/s41584-018-0021-9
   PubMed Web of Science ®Google Scholar
• Bagnato G, Roberts WN, Roman J, et al. A systematic review of overlapping microRNA patterns in systemic sclerosis and idiopathic pulmonary fibrosis. Eur Respir Rev. 2017;26(144):160125. doi:10.1183/16000617.0125-2016
   PubMed Web of Science ®Google Scholar
• Zuo X, Zhang L, Luo H, et al. Systematic approach to understanding the pathogenesis of systemic sclerosis. Clin Genet. 2017;92(4):365–371. doi:10.1111/cge.12946
   PubMed Web of Science ®Google Scholar
• Artlett CM, Sassi-Gaha S, Hope JL, et al. Mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis. Arthritis Res Ther. 2017;19(1):144. doi:10.1186/s13075-017-1331-z
   PubMed Web of Science ®Google Scholar
• Zhang L, Wu H, Zhao M, et al. Meta-analysis of differentially expressed microRNAs in systemic sclerosis. Int J Rheum Dis. 2020;23(10):1297–1304. doi:10.1111/1756-185X.13924
   PubMed Web of Science ®Google Scholar
• He Y, Liu H, Wang S, Chen Y. In silico detection and characterization of microRNAs and their target genes in microRNA microarray datasets from patients with systemic sclerosis-interstitial lung disease. DNA Cell Biol. 2019;38(9):933–944. doi:10.1089/dna.2019.4780
   PubMed Web of Science ®Google Scholar
• Hoffmann-Vold AM, Weigt SS, Palchevskiy V, et al. Augmented concentrations of CX3CL1 are associated with interstitial lung disease in systemic sclerosis. PLoS One. 2018;13(11):e0206545. doi:10.1371/journal.pone.0206545
   PubMed Web of Science ®Google Scholar
• Rajasekaran S, Vaz M, Reddy SP. Fra-1/AP-1 transcription factor negatively regulates pulmonary fibrosis in vivo. PLoS One. 2012;7(7):e41611. doi:10.1371/journal.pone.0041611
   PubMed Web of Science ®Google Scholar
• Mariotti B, Servaas NH, Rossato M, et al. The long non-coding RNA NRIR drives IFN-response in monocytes: implication for systemic sclerosis. Front Immunol. 2019;10:100. doi:10.3389/fimmu.2019.00100
   PubMed Web of Science ®Google Scholar
• Abd-Elmawla MA, Hassan M, Elsabagh YA, et al. Deregulation of long noncoding RNAs ANCR, TINCR, HOTTIP and SPRY4-IT1 in plasma of systemic sclerosis patients: SPRY4-IT1 as a novel biomarker of scleroderma and its subtypes. Cytokine. 2020;133:155124. doi:10.1016/j.cyto.2020.155124
   PubMed Web of Science ®Google Scholar
• Takata M, Pachera E, Frank-Bertoncelj M, et al. OTUD6B-AS1 might be a novel regulator of apoptosis in systemic sclerosis. Front Immunol. 2019;10:1100. doi:10.3389/fimmu.2019.01100
   PubMed Web of Science ®Google Scholar
• Pachera E, Assassi S, Salazar GA, et al. Long noncoding RNA H19X is a key mediator of TGF-beta-driven fibrosis. J Clin Invest. 2020;130(9):4888–4905. doi:10.1172/JCI135439
   PubMed Web of Science ®Google Scholar
• Muntyanu A, Le M, Ridha Z, et al. Novel role of long non-coding RNAs in autoimmune cutaneous disease. J Cell Commun Signal. 2021. doi:10.1007/s12079-021-00639-x
   PubMed Web of Science ®Google Scholar
• Wang Z, Jinnin M, Nakamura K, et al. Long non-coding RNA TSIX is upregulated in scleroderma dermal fibroblasts and controls collagen mRNA stabilization. Exp Dermatol. 2016;25(2):131–136. doi:10.1111/exd.12900
   PubMed Web of Science ®Google Scholar
• Wasson CW, Ross RL, Wells R, et al. Long non-coding RNA HOTAIR induces GLI2 expression through Notch signalling in systemic sclerosis dermal fibroblasts. Arthritis Res Ther. 2020;22(1):286. doi:10.1186/s13075-020-02376-9
   PubMed Web of Science ®Google Scholar
• Dolcino M, Tinazzi E, Puccetti A, et al. In systemic sclerosis, a unique long non coding RNA regulates genes and pathways involved in the three main features of the disease (vasculopathy, fibrosis and autoimmunity) and in carcinogenesis. J Clin Med. 2019;8(3):320. doi:10.3390/jcm8030320
   PubMed Web of Science ®Google Scholar
• Servaas NH, Mariotti B, van der Kroef M, et al. Characterization of long non-coding RNAs in systemic sclerosis monocytes: a potential role for PSMB8-AS1 in altered cytokine secretion. Int J Mol Sci. 2021;22(9):4365. doi:10.3390/ijms22094365
   PubMed Web of Science ®Google Scholar
• Wermuth PJ, Piera-Velazquez S, Jimenez SA. Exosomes isolated from serum of systemic sclerosis patients display alterations in their content of profibrotic and antifibrotic microRNA and induce a profibrotic phenotype in cultured normal dermal fibroblasts. Clin Exp Rheumatol. 2017;35 Suppl 106(4):21–30.
   PubMed Web of Science ®Google Scholar
• Fang S, Xu C, Zhang Y, et al. Umbilical cord-derived mesenchymal stem cell-derived exosomal MicroRNAs suppress myofibroblast differentiation by inhibiting the transforming growth factor-beta/SMAD2 pathway during wound healing. Stem Cells Transl Med. 2016;5(10):1425–1439. doi:10.5966/sctm.2015-0367
   PubMed Web of Science ®Google Scholar